Researchers at the Medical University of South Carolina found that M10, a naturally occurring small peptide, appeared to effectively reduce lung fibrosis in a mouse model of systemic sclerosis, a finding that might lead the way to new treatments for lung fibrosis. Systemic sclerosis can be viewed as the archetypal fibrotic disease,…
Small Peptide Shows Promise in Reducing Lung Fibrosis in a Mouse Model
Pulmonary fibrosis is a really difficult disease to diagnose. To ensure you get an accurate diagnosis and to determine the type of PF you have, doctors from a variety of specialties, including pulmonologists (respirologists), radiologists, rheumatologists, and pathologists have to work together. To learn more about…
https://www.youtube.com/watch?v=azsl8oa76Vs Boehringer Ingelheim shared this video where they show you how hard it is to live with IPF. Pulmonary fibrosis patients feel like they have to put their lives on hold, all the time. Making pit stops to get their breath again and not…
Galapagos NV recently announced the launch of an exploratory Phase 2a clinical trial, called FLORA, evaluating the company’s proprietary drug GLPG1690 in patients with idiopathic pulmonary fibrosis (IPF). Esbriet (pirfenidone) and Ofev (nintedanib) are the only approved therapies for the treatment of IPF, and both have been shown…
This video from Boehringer Ingelheim Idiopathic Pulmonary Fibrosis shows how it is to live with IPF, how every single breath counts for the patients living with this disease. As read in the video description, for these patients, “it’s not about the number of breaths…
Pulmonary fibrosis (PF) is a respiratory disease characterized by the presence of scarred tissue in the lungs. “It can be challenging to figure out what caused your pulmonary fibrosis. Sometimes doctors are able to identify one or more causes of your disease, but it is also common…
The Pulmonary Fibrosis Foundation (PFF) recently announced the launch of the PFF Patient Registry, which will comprise the foundation’s first comprehensive collection of data from pulmonary fibrosis (PF) patients across America. The first patient was enrolled last week, kicking off patient enrollment in the registry,…
In this video from MD Magazine TV, watch Dr. Danny McBryan, from Boehringer Ingelheim Pharmaceuticals, talk about the data his company published at CHEST, about how hard it is to find medications and treatments for IPF patients, and how having even one viable…
It’s known that genetics may be a cause of the development of pulmonary fibrosis, but in the majority of cases, the cause is unknown — a condition known as idiopathic pulmonary fibrosis. Each patient tends to have an individualized experience with the disease, which can progress faster or slower from…
PFF Care Center Network is a group of medical centers which dedicate their work to improving the lives of those living with pulmonary fibrosis. According to the Pulmonary Fibrosis Foundation, these kinds of centers are expanding and keep growing. Their main purpose is to treat patients with…
